Literature DB >> 8988680

Patterns of nodal and distant metastasis based on histologic varieties in differentiated carcinoma of the thyroid.

A R Shaha1, J P Shah, T R Loree.   

Abstract

BACKGROUND: Understanding of differentiated carcinoma of the thyroid has improved in recent years with the definition of prognostic factors and risk group analysis. We intend to review our experience of differentiated thyroid cancer in relation to the risk of nodal and distant metastasis based on various histologic subgroups.
METHODS: This is a retrospective review of a consecutive series of 1,038 previously untreated patients with differentiated carcinoma of the thyroid treated over a period of 55 years. Univariate and multivariate analysis of various prognostic factors was performed. The incidence of nodal and distant metastasis was analyzed based on various histologic varieties of differentiated thyroid cancer.
RESULTS: There were 337 male and 701 female patients. The various histologic subgroups included papillary (810), follicular (169), and Hurthle cell cancer (59). The cumulative risk of nodal metastasis based on histological group was 61%, 30%, and 21% for papillary, follicular, and Hurthle cell variety, respectively. The risk of distant metastasis for the same histologic varieties was 10%, 22%, and 33%, respectively. The 5- and 20-year survival for these histologic subgroups was papillary (94% and 87%, respectively), follicular (87% and 81%), and Hurthle cell tumors (81% and 65%; P < 0.001).
CONCLUSIONS: The incidence of nodal metastasis is highest in the papillary subgroup; however, the incidence of distant metastasis was 33% in the Hurthle cell variety. The risk of nodal and distant metastasis varies considerably based on individual histologic variety.

Entities:  

Mesh:

Year:  1996        PMID: 8988680     DOI: 10.1016/s0002-9610(96)00310-8

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  66 in total

Review 1.  Unusual types of thyroid cancer.

Authors:  K B Ain
Journal:  Rev Endocr Metab Disord       Date:  2000-04       Impact factor: 6.514

2.  Surgical decision making in the management of well-differentiated thyroid cancer.

Authors:  Natalya Chernichenko; Ashok R Shaha
Journal:  Indian J Surg Oncol       Date:  2012-05-01

3.  Primary Thyroid Carcinoma with Low-Risk Histology and Distant Metastases: Clinicopathologic and Molecular Characteristics.

Authors:  Bin Xu; R Michael Tuttle; Mona M Sabra; Ian Ganly; Ronald Ghossein
Journal:  Thyroid       Date:  2017-02-01       Impact factor: 6.568

4.  Risk factors for local recurrence following lateral neck dissection for papillary thyroid carcinoma.

Authors:  Marco Raffaelli; Carmela De Crea; Luca Sessa; Serena Elisa Tempera; Amanda Belluzzi; Celestino P Lombardi; Rocco Bellantone
Journal:  Endocrine       Date:  2018-10-19       Impact factor: 3.633

5.  Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E).

Authors:  Amjad Husain; Nina Hu; Peter M Sadow; Carmelo Nucera
Journal:  Cancer Lett       Date:  2015-07-17       Impact factor: 8.679

6.  Thyroid Hürthle cell tumors: research of potential markers of malignancy.

Authors:  G Donatini; A Beaulieu; M Castagnet; J-L Kraimps; P Levillain; G Fromont
Journal:  J Endocrinol Invest       Date:  2015-07-19       Impact factor: 4.256

7.  Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis?

Authors:  Elif Hindié; Didier Mellière; Françoise Lange; Iyad Hallaj; Claire de Labriolle-Vaylet; Christian Jeanguillaume; Jacques Lange; Léon Perlemuter; Serge Askienazy
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-07       Impact factor: 9.236

8.  Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases.

Authors:  M M Sabra; J M Dominguez; R K Grewal; S M Larson; R A Ghossein; R M Tuttle; J A Fagin
Journal:  J Clin Endocrinol Metab       Date:  2013-03-26       Impact factor: 5.958

9.  Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.

Authors:  Kevin B Kim; Maria E Cabanillas; Alexander J Lazar; Michelle D Williams; Deborah L Sanders; Joseph L Ilagan; Keith Nolop; Richard J Lee; Steven I Sherman
Journal:  Thyroid       Date:  2013-07-17       Impact factor: 6.568

10.  Discrimination of benign and malignant thyroid nodules by molecular profiling.

Authors:  David J Finley; Baixin Zhu; Catherine B Barden; Thomas J Fahey
Journal:  Ann Surg       Date:  2004-09       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.